Conference Call with Cohance Lifesciences Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Cohance Lifesciences announced Q1FY26 results Company reported revenue of Rs 5,493 million, up 13% YoY growth exceeds 25%. Gross margins expanded to 73.0% from 68.4% in Q1FY25. EBITDA was Rs 1,314 million with a margin of 23.9%. Vivek Sharma, Executive Chairman, said: "Q1FY26 has been an important start to the year, with progress not just in execution but in strengthening the foundation we have built. Our growing presence in niche modalities like ADCs and oligonucleotides, combined with a deepening global customer base, positions Cohance for accelerated growth. With strengthened leadership and the guidance of our External Advisory Board, we remain committed to becoming a global technology-led CDMO, delivering long-term value for all stakeholders." Result PDF
Pharmaceuticals company Cohance Lifesciences announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Cohance reported revenue of Rs 8,412 million, up 20% YoY. Adjusted EBITDA stood at Rs 2,632 million for Q4FY25 compared to Rs 2,554 million for Q4FY24 and adjusted EBITDA margin was 31.3%, reflecting continued investments in people and infrastructure across the platform. Adjusted PAT stood at Rs 1,441 million for Q4FY25 compared to Rs 1,721 million for Q4FY24 FY25 Financial Highlights: FY25 revenue grew 9.1% YoY to Rs 26103 million on a combined platform. The company generated free cash flow of Rs 3.61 billion during the year and closed FY25 with Rs 2.90 billion in cash and bank balances, despite incurring M&A; investments of Rs 8.06 billion. Adjusted EBITDA stood at Rs 8,781 million for FY25 compared to Rs 8,534 million for FY24 Adjusted PAT stood at Rs 5,463 million for FY25 compared to Rs 5,739 million for FY24 Vivek Sharma, Executive Chairman, said: “FY25 was a year of strategic transformation as we built a USD 335 million global CDMO platform with differentiated capabilities across modalities. With the merger now behind us, we move forward under the Cohance identity— a technology-led CDMO focused on science, speed, and reliability. We are excited about the road ahead and remain committed to our goal of becoming a USD 1 billion (Rs 85 billion) CDMO by 2030. The foundation is strong, our pipeline is strengthen, and FY26 will be a year of acceleration as we deepen strategic relationships and scale up differentiated platforms like ADCs and Oligos” Result PDF
Conference Call with Cohance Lifesciences Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.